Business
Sumitomo Pharma America to Present New Investigational Data at the 2025 American Society of Hematology Annual Meeting
Sumitomo Pharma America, Inc. (SMPA) today announced three oral presentations and one poster presentation at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition taking place in Orlando, Florida, from December 6-9, 2025. The presentations will include new clinical data supporting enzomenib, an investigational, oral small molecule menin inhibitor being researched as a monotherapy and in combination with venetoclax and azacitidine (VEN/AZA) for relapsed or refractory acute leu
About this update from Sumitomo Pharma Co.ltd.
[{"type":"list","items":[{"val":[{"type":"text","content":"New data from Phase 1/2 study of enzomenib (DSP-5336) in patients with relapsed/refractory acute myeloid leukemia (AML) show promising clinical activity across a wide range of potentially therapeutic doses","length":205,"tagName":"p"}]},{"val":[{"type":"text","content":"Preliminary data from Phase 1 study of enzomenib in combination with venetoclax and azacitidine in patients with relapsed/refractory AML show encouraging early clinical activity and that the combination is well tolerated","length":220,"tagName":"p"}]},{"val":[{"type":"text","content":"Preliminary data from Phase 1/2 study of nuvisertib (TP-3654) in combination with momelotinib in patients with relapsed/refractory myelofibrosis show encouraging early clinical activity ","length":185,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":610,"olType":false},{"type":"text","content":"MARLBOROUGH, Mass., Nov. 3, 2025 /PRNewswire/ -- Sumitomo Pharma America, Inc. (SMPA) today announced three oral presentations and one poster presentation at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition taking place in Orlando, Florida, from December 6-9, 2025. The presentations will include new clinical data supporting enzomenib, an investigational, oral small molecule menin inhibitor being researched as a monotherapy and in combination with venetoclax and azacitidine (VEN/AZA) for relapsed or refractory acute leukemia, and nuvisertib, an oral investigational highly selective small molecule PIM1 kinase inhibitor being evaluated as a monotherapy and in combination with momelotinib (MMB) for the treatment of relapsed or refractory myelofibrosis (MF).","length":797,"tagName":"p"},{"type":"image","alt":"SMPA Logo (PRNewsfoto/Sumitomo Pharma America)","displaySize":"","headline":null,"caption":"SMPA Logo (PRNewsfoto/Sumitomo Pharma America)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":54,"url":"https://media.zenfs.com/en/prnewswire.com/36c67330cea4d215e392946ca6461778"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/s5pb1ghAEWSETpWimf6IZA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTk1O2NmPXdlYnA-/https://media.zenfs.com/en/prnewswire.com/36c67330cea4d215e392946ca6461778","width":400,"height":54}},"href":"https://mma.prnewswire.com/media/2206351/Sumitomo_Pharma_updated_Logo.html"...